Multicenter, Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States

Trial Profile

Multicenter, Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Macitentan (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Acronyms OrPHeUS
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 13 Nov 2017 Planned End Date changed from 31 Dec 2018 to 15 Jan 2018.
    • 13 Nov 2017 Planned primary completion date changed from 31 Dec 2018 to 15 Jan 2018.
    • 22 Aug 2017 Status changed from not yet recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top